AI Insight
This commentary discusses the evolving treatment approaches for obesity and type 2 diabetes, two interconnected chronic progressive diseases. The article highlights a conceptual shift in obesity treatment from focusing solely on weight loss to improving overall health outcomes, while noting that weight loss remains an important therapeutic target for type 2 diabetes management. The commentary emphasizes the need for integrated prevention and treatment strategies ranging from policy interventions addressing obesogenic environments to personalized behavioral, pharmacological, and surgical approaches.
Why it matters
This perspective is important for clinical practice as it frames modern approaches to managing two of the most prevalent metabolic diseases globally. The recognition of the need for comprehensive, personalized treatment strategies rather than single-target interventions could improve patient outcomes and guide healthcare policy development.
Obesity and type 2 diabetes are closely connected chronic progressive diseases that require an integrated prevention and treatment approach, ranging from policy measures to address the obesogenic environment to personalised behaviour, pharmacological, or surgical interventions.1 In recent years, conceptual changes were introduced for the treatment of obesity and type 2 diabetes. In the treatment of people living with obesity, the focus shifted from simple weight loss to improving health,1 but there is consensus in the treatment of type 2 diabetes that weight loss represents an important target.
Source: [Comment] Treatment potential of oral small-molecule GLP-1 receptor agonists